%PDF-1.7
%
1 0 obj
<>>>
endobj
2 0 obj
<>stream
2015-10-01T08:00:46-04:00
2015-10-01T08:00:47-04:00
2015-10-01T08:00:47-04:00
Adobe InDesign CC 2014 (Windows)
uuid:219a7820-42ef-4f03-a9ec-f57499f28722
xmp.did:4A42F9656056E111960DCE8E95F0DF9D
xmp.id:bf4e5478-97c0-e140-bc98-9b191f317e3b
proof:pdf
xmp.iid:ce6f7540-0dbb-9148-a630-e48adabf8c30
xmp.did:d1980911-68a3-5943-809d-bb12dd1e77dc
xmp.did:4A42F9656056E111960DCE8E95F0DF9D
default
converted
from application/x-indesign to application/pdf
Adobe InDesign CC 2014 (Windows)
/
2015-10-01T08:00:46-04:00
application/pdf
Adobe PDF Library 11.0
False
endstream
endobj
3 0 obj
<>
endobj
5 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page>>
endobj
6 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/Properties<>/XObject<>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page>>
endobj
17 0 obj
<>stream
BT
0 0 0 1 k
/GS0 gs
/TT0 1 Tf
7 0 0 7 60.48 22.6817 Tm
(2 )Tj
/Span<>> BDC
( )Tj
EMC
59.297 0 Td
[(Pharmacology W)54.6(atch)]TJ
4.081 0 0 4.081 535.1605 25.0127 Tm
(\256)Tj
ET
q
0 g
/GS1 gs
/Fm0 Do
Q
BT
/T1_0 1 Tf
-0.01 Tc 7 0 0 7 40.75 269 Tm
(PHARMACOLOGY WATCH)Tj
/T1_1 1 Tf
0 Tc 6 0 0 6 127.892 269 Tm
(\231 )Tj
1.23 0 Td
( )Tj
-0.01 Tc -15.754 -1.167 Td
[(is published monthly by AHC Media, LLC. Copyright \251 2015 AHC Media, L\
LC.)-10( )]TJ
/T1_2 1 Tf
0.01 Tw 8 0 0 8 40.75 252 Tm
(Editor)Tj
/T1_3 1 Tf
0 Tw 0 -1.25 TD
(William T. Elliott, MD, FACP)Tj
0 Tc 12.43 0 Td
( )Tj
/T1_1 1 Tf
-0.01 Tc -12.43 -1.25 Td
(Chair, Formulary Committee, Kaiser Permanente, California Division)Tj
0 Tc 29.325 0 Td
( )Tj
-0.01 Tc -29.325 -1.25 Td
[(Assistant Clinical Professor of Medicine,)-10( )]TJ
0 Tc 17.455 0 Td
( )Tj
-0.01 Tc -17.455 -1.25 Td
(University of California, San Francisco)Tj
/T1_2 1 Tf
T*
(Executive Editor:)Tj
/T1_1 1 Tf
( Leslie Coplin)Tj
/T1_2 1 Tf
T*
(Associate Managing Editor:)Tj
/T1_1 1 Tf
( Jonathan Springston)Tj
6 0 0 6 40.75 180.5 Tm
[(This is an educational publication designed to present scientific inform\
ation and opinion to)-10( )]TJ
0 -1.167 TD
[(health professionals, stimulate thought, and further investigation. It d\
oes not provide advice)-10( )]TJ
0 -1.167 TD
[(regarding medical diagnosis or treatment for any individual case. It is \
not intended for the)-10( )]TJ
0.01 Tw 0 -1.167 TD
(layman.)Tj
0.01 Tc 0 Tw 0 -1.917 TD
(STATEMENT OF FINANCIAL DISCLOSURE)Tj
-0.01 Tc 0 -1.167 TD
[(To reveal any potential bias in this publication, and in accordance with\
Accreditation Council)-9.9( )]TJ
0 -1.167 TD
[(for Continuing Medical Education guidelines, Dr. Elliott \(editor\), Ms.\
Coplin \(executive)-10( )]TJ
T*
[(editor\), and Mr. Springston \(associate managing editor\) report no fin\
ancial relationships)-10( )]TJ
0 -1.167 TD
(relevant to this field of study.)Tj
ET
/CS0 CS 1 SCN
0.25 w 4 M
/GS1 gs
36.125 45.125 251.75 233.75 re
S
/CS0 cs 0.1 scn
122.4 50.76 160.85 69.12 re
f
BT
0 0 0 1 k
/GS0 gs
/T1_2 1 Tf
0.05 Tc 8 0 0 8 126.9 108.1801 Tm
[(SUBSCRIBER INFORMA)92(TION)]TJ
-0.01 Tc 7 0 0 7 126.9 97.9041 Tm
(Customer Service: \(800\) 688-2421)Tj
/T1_1 1 Tf
6 0 0 6 126.9 90.9041 Tm
(Email Address: jonathan.springston@ahcmedia.com)Tj
0 -1.167 TD
(Website: AHCMedia.com)Tj
0 -1.917 TD
[(Address Correspondence to: AHC Media, One Atlanta)-10( )]TJ
0 -1.167 TD
[(Plaza, 950 East Paces Ferry Road NE, Suite 2850, Atlanta,)-9.9( )]TJ
T*
[(GA 30326.)-10( )]TJ
ET
/PlacedGraphic /MC0 BDC
EMC
q
44.685 73.418 70.72 32.443 re
W n
/GS1 gs
q 1 0 0 1 52.0285 92.6745 cm
0 0 m
-0.027 0 l
-0.163 -0.531 -0.313 -1.171 -0.463 -1.715 c
-1.171 -3.975 l
1.184 -3.975 l
0.463 -1.715 l
0.286 -1.157 0.136 -0.531 0 0 c
f
Q
q 1 0 0 1 70.4899 86.0851 cm
0 0 m
0.667 0 1.375 0.136 1.824 0.327 c
2.097 -0.994 l
1.702 -1.184 0.831 -1.402 -0.286 -1.402 c
-3.199 -1.402 -4.969 0.422 -4.969 3.227 c
-4.969 6.249 -2.859 8.073 -0.054 8.073 c
1.048 8.073 1.824 7.842 2.165 7.665 c
1.811 6.331 l
1.375 6.521 0.762 6.685 0.014 6.685 c
-1.852 6.685 -3.199 5.514 -3.199 3.308 c
-3.199 1.28 -2.028 0 0 0 c
-6.127 -1.252 m
-7.801 -1.252 l
-7.801 2.791 l
-11.681 2.791 l
-11.681 -1.252 l
-13.356 -1.252 l
-13.356 7.924 l
-11.681 7.924 l
-11.681 4.248 l
-7.801 4.248 l
-7.801 7.924 l
-6.127 7.924 l
h
-16.174 -1.252 m
-17.005 1.348 l
-19.905 1.348 l
-20.694 -1.252 l
-22.423 -1.252 l
-19.483 7.924 l
-17.345 7.924 l
-14.364 -1.252 l
h
-25.805 -12.253 31.616 31.616 re
-25.805 19.363 m
f
Q
q 1 0 0 1 88.2162 88.5766 cm
0 0 m
-0.054 1.185 -0.123 2.614 -0.109 3.853 c
-0.15 3.853 l
-0.449 2.736 -0.831 1.498 -1.239 0.34 c
-2.587 -3.635 l
-3.866 -3.635 l
-5.092 0.286 l
-5.446 1.457 -5.772 2.709 -6.018 3.853 c
-6.045 3.853 l
-6.086 2.655 -6.14 1.198 -6.208 -0.055 c
-6.413 -3.744 l
-7.978 -3.744 l
-7.365 5.432 l
-5.16 5.432 l
-3.962 1.743 l
-3.635 0.667 -3.349 -0.422 -3.118 -1.443 c
-3.077 -1.443 l
-2.832 -0.449 -2.519 0.681 -2.165 1.756 c
-0.899 5.432 l
1.28 5.432 l
1.811 -3.744 l
0.177 -3.744 l
h
f
Q
q 1 0 0 1 95.8269 88.8489 cm
0 0 m
0.014 0.613 -0.259 1.62 -1.375 1.62 c
-2.41 1.62 -2.846 0.681 -2.914 0 c
h
-2.914 -1.171 m
-2.873 -2.369 -1.947 -2.886 -0.871 -2.886 c
-0.095 -2.886 0.449 -2.764 0.966 -2.587 c
1.211 -3.73 l
0.64 -3.975 -0.15 -4.152 -1.103 -4.152 c
-3.254 -4.152 -4.52 -2.832 -4.52 -0.803 c
-4.52 1.035 -3.404 2.764 -1.28 2.764 c
0.871 2.764 1.579 0.994 1.579 -0.463 c
1.579 -0.776 1.552 -1.021 1.525 -1.171 c
h
f
Q
q 1 0 0 1 103.1923 88.6991 cm
0 0 m
0 0.136 -0.014 0.313 -0.041 0.449 c
-0.191 1.089 -0.721 1.62 -1.484 1.62 c
-2.559 1.62 -3.158 0.667 -3.158 -0.558 c
-3.158 -1.783 -2.559 -2.668 -1.497 -2.668 c
-0.817 -2.668 -0.218 -2.205 -0.054 -1.484 c
-0.014 -1.334 0 -1.171 0 -0.994 c
h
1.675 5.8 m
1.675 -2.001 l
1.675 -2.682 1.702 -3.417 1.729 -3.866 c
0.245 -3.866 l
0.163 -2.818 l
0.136 -2.818 l
-0.259 -3.553 -1.062 -4.016 -2.015 -4.016 c
-3.608 -4.016 -4.86 -2.668 -4.86 -0.626 c
-4.874 1.593 -3.485 2.914 -1.892 2.914 c
-0.98 2.914 -0.327 2.546 -0.027 2.056 c
0 2.056 l
0 5.8 l
h
f
Q
106.664 91.463 1.675 -6.63 re
106.664 84.833 m
108.448 93.314 m
108.448 92.824 108.08 92.416 107.495 92.416 c
106.936 92.416 106.569 92.824 106.569 93.314 c
106.569 93.832 106.95 94.227 107.508 94.227 c
108.08 94.227 108.434 93.832 108.448 93.314 c
f
q 1 0 0 1 113.6622 88.0729 cm
0 0 m
-1.184 0.014 -2.315 -0.231 -2.315 -1.239 c
-2.315 -1.892 -1.892 -2.192 -1.361 -2.192 c
-0.681 -2.192 -0.204 -1.756 -0.041 -1.28 c
0 -1.157 0 -1.035 0 -0.912 c
h
1.634 -1.647 m
1.634 -2.246 1.661 -2.832 1.743 -3.24 c
0.231 -3.24 l
0.109 -2.505 l
0.068 -2.505 l
-0.327 -3.022 -1.021 -3.39 -1.892 -3.39 c
-3.226 -3.39 -3.975 -2.423 -3.975 -1.416 c
-3.975 0.245 -2.492 1.103 -0.041 1.089 c
-0.041 1.198 l
-0.041 1.634 -0.218 2.355 -1.389 2.355 c
-2.042 2.355 -2.723 2.151 -3.172 1.865 c
-3.499 2.954 l
-3.009 3.254 -2.151 3.54 -1.103 3.54 c
1.021 3.54 1.634 2.192 1.634 0.735 c
h
f
Q
Q
BT
/T1_4 1 Tf
-0.03 Tc 10 0 0 10 36 736.2775 Tm
[(rather than giving it at age 50, according to a new study in)-30( )]TJ
0.03 Tw 0 -1.2 TD
(the )Tj
/T1_5 1 Tf
0 Tw 1.491 0 Td
(Annals of Internal Medicine)Tj
/T1_4 1 Tf
[(. The FDA has approved the)-30( )]TJ
-1.491 -1.2 Td
[(vaccine to be given at age 50; however)111(, the ACIP recommends)-29.9( )]TJ
T*
[(giving it at age 60. The new study examined the incidence of)-30( )]TJ
T*
[(herpes zoster \(HZ\) and postherpetic neuralgia \(PHN\) and)-30( )]TJ
T*
[(incremental cost per quality-adjusted life-year \(QAL)111(Y\) saved.)-30( )]TJ
T*
[(Data were obtained from several U.S.-based vaccine studies.)-30( )]TJ
T*
[(For every 1000 people receiving the vaccine at age 50, 25 HZ)-30( )]TJ
T*
[(cases and 1 PHN case could be prevented. The incremental)-30( )]TJ
T*
[(cost-effectiveness ratio \(ICER\) for the shingles vaccine vs no)-30( )]TJ
T*
[(vaccine was more than $320,000 per QAL)111(Y)129(. The ICER can be)-30( )]TJ
T*
[(reduced to less than $100,000 only if the vaccine is priced at)-30( )]TJ
/C2_0 1 Tf
0 Tc T*
<0064>Tj
/T1_4 1 Tf
-0.03 Tc 0.519 0 Td
[( $80 or if there is a decrease in the rate at which the ef\036cacy)-30( )]TJ
-0.519 -1.2 Td
[(of the vaccine wanes. The authors concluded that the shingles)-30( )]TJ
T*
[(vaccine does not represent a good value for patients at age)-30( )]TJ
T*
[(50 years, according to generally accepted standards, and they)-30( )]TJ
T*
[(agreed with the ACIP recommendation not to recommend)-30( )]TJ
T*
(vaccine for this age group \()Tj
/T1_5 1 Tf
(Ann Intern Med)Tj
/T1_4 1 Tf
[( published online)-30( )]TJ
T*
(Sept. 8, 2015; doi:10.7326/M15-0093\).)Tj
/TT0 1 Tf
0 Tc 14 0 0 14 36 492.2775 Tm
[(Spironolactone Effective Add-)-18(on)]TJ
( )Tj
0 -1.143 TD
[(for R)17.4(esistant Hypertension P)37(atients)]TJ
/T1_4 1 Tf
-0.03 Tc 10 0 0 10 36 464.2775 Tm
[(For patients with resistant hypertension who are already on)-30( )]TJ
0 -1.2 TD
[(a three-drug regimen, spironolactone is an effective add-on,)-30( )]TJ
T*
(according to a new study from )Tj
/T1_5 1 Tf
0.03 Tw (The)Tj
/T1_4 1 Tf
0 Tc 0 Tw ( )Tj
/T1_5 1 Tf
-0.03 Tc 0.03 Tw 14.427 0 Td
(Lancet)Tj
/T1_4 1 Tf
0 Tw (. In a double-)Tj
-14.427 -1.2 Td
[(blind, placebo-controlled, crossover trial, 355 subjects with)-30( )]TJ
T*
(systolic readings > 140 mmHg \(or )Tj
/C2_0 1 Tf
0 Tc <0074>Tj
/T1_4 1 Tf
-0.03 Tc 14.476 0 Td
[( 135 mmHg for diabetics\))-30( )]TJ
-14.476 -1.2 Td
[(were evaluated. All patients were already taking maximally)-30( )]TJ
T*
[(tolerated doses of three drugs \(ACEI/ARB, calcium-channel)-30( )]TJ
T*
[(blocker)111(, and a diuretic\). They then rotated all patients)-30( )]TJ
T*
(through 12 weeks of treatment with spironolactone \(25-)Tj
T*
[(50 mg\), bisoprolol \(5-10 mg\), doxazosin modi\036ed release)-30( )]TJ
T*
[(\(4-8 mg\), and placebo, in addition to their baseline drugs.)-30( )]TJ
T*
[(Spironolactone was superior to placebo in lowering systolic)-30( )]TJ
T*
[(blood pressure by 8.7 mmHg \(95% con\036dence interval; -9.72)-30( )]TJ
T*
(to -7.69; )Tj
/T1_5 1 Tf
0 Tc (P)Tj
/T1_4 1 Tf
-0.03 Tc 4.283 0 Td
[( < 0.0001\). Spironolactone was also superior to)-30( )]TJ
-4.283 -1.2 Td
[(the mean of the two other active treatments \(doxazosin and)-30.1( )]TJ
T*
[(bisoprolol; -4.26 mmHg\) and each drug individually \(-4.03)-30( )]TJ
27 45.2 Td
(mmHg vs doxazosin and -4.48 mmHg vs bisoprolol; )Tj
/T1_5 1 Tf
0 Tc (P)Tj
/T1_4 1 Tf
-0.03 Tw 22.091 0 Td
( < )Tj
-0.03 Tc 0 Tw -22.091 -1.2 Td
[(0.0001 for all comparisons\). Six of the 285 patients taking)-30( )]TJ
T*
[(spironolactone had elevated potassium readings on one)-29.9( )]TJ
T*
[(occasion. The authors concluded that spironolactone was)-30( )]TJ
T*
[(the most effective add-on drug for treatment of resistant)-30( )]TJ
T*
[(hypertension, suggesting that sodium retention plays a role)-30( )]TJ
T*
(in this condition \()Tj
/T1_5 1 Tf
0.03 Tw (Lancet)Tj
/T1_4 1 Tf
0 Tw ( published online; doi: http://dx.doi.)Tj
0.03 Tw T*
(org/10.1016/S0140-6736\(15\)00257-3\).)Tj
/TT0 1 Tf
0 Tc 0 Tw 14 0 0 14 306 624.2775 Tm
[(FD)17.4(A Actions)]TJ
/T1_4 1 Tf
-0.03 Tc 10 0 0 10 306 612.2775 Tm
[(Despite the favorable news for empagli\037ozin, the news)-30( )]TJ
T*
[(for another SGL)92(T2 inhibitor is not so good. The FDA)-30( )]TJ
T*
[(has strengthened the warning regarding bone loss and)-30( )]TJ
T*
[(fracture risk associated with the diabetes drug canagli\037ozin)-30( )]TJ
T*
[(\(Invokana\). The FDA warning notes that fractures can occur)-30( )]TJ
T*
[(as early as 12 weeks after starting canagli\037ozin. The drug has)-30( )]TJ
T*
[(also been linked to decreases in bone mineral density at the)-30( )]TJ
T*
[(hip and lower spine. The FDA is evaluating whether other)-30( )]TJ
T*
[(SGL)92(T2 inhibitors, dapagli\037ozin \(Farxiga\) and empagli\037ozin)-30( )]TJ
T*
(\(Jardiance\), have similar effects on bone \()Tj
/CS0 cs 1 scn
/GS1 gs
0.03 Tw [(www)92(.fda.gov/Safety/)]TJ
T*
(Medwatch)Tj
0 0 0 1 k
/GS0 gs
[(\).)-29.9( )]TJ
0 Tw 0 -2.4 TD
[(The FDA has approved cariprazine to treat schizophrenia)-30( )]TJ
0 -1.2 TD
[(and bipolar disorder in adults. The drug is a partial agonist)-30( )]TJ
T*
[(of D2 and D3 dopamine and 5-HT1A serotonin receptors.)-30( )]TJ
T*
[(It is taken orally once a day at a recommended dosage of)-30( )]TJ
T*
[(3-6 mg for bipolar manic or mixed episodes and 1.5-6 mg)-30( )]TJ
T*
[(for schizophrenia. Ef\036cacy in treating schizophrenia was)-30( )]TJ
T*
[(demonstrated in three studies of more than 1700 patients in)-30( )]TJ
T*
[(which the drug showed superiority to placebo. Ef\036cacy in)-30( )]TJ
T*
[(treating bipolar disorder was shown in three trials of more)-30( )]TJ
T*
[(than 1000 subjects in which the drug was shown to reduce)-29.9( )]TJ
T*
[(the symptoms of bipolar disorder in each trial. Cariprazine,)-30( )]TJ
T*
[(similar to all FDA-approved drugs for schizophrenia and)-30( )]TJ
-0.001 Tw T*
[(bipolar disorder)111(, carries a boxed warning regarding higher risk)-30( )]TJ
0 Tw T*
[(of death in patients with dementia-related psychosis. Most)-30( )]TJ
T*
[(common side effects are extrapyramidal symptoms, including)-30( )]TJ
T*
[(tremor)111.1(, slurred speech, involuntary muscle movements,)-30( )]TJ
T*
[(akathisia, and gastrointestinal symptoms. Cariprazine is)-30( )]TJ
T*
[(manufactured by Forest Laboratories and distributed by)-30( )]TJ
T*
[(Actavis Pharma as V)67(raylar)111(.)-30( )]TJ
0 -2.4 TD
[(The FDA has approved insulin degludec, a new long-acting)-30( )]TJ
0 -1.2 TD
[(insulin analog, as a standalone product and in combination)-30( )]TJ
T*
[(with insulin aspart \(70/30\). Insulin degludec has a duration)-30( )]TJ
T*
[(of action of up to 40 hours, the longest of any insulin analog,)-30( )]TJ
T*
[(allowing its use as once-daily basal insulin. The ef\036cacy and)-29.9( )]TJ
T*
[(safety of insulin degludec in combination with mealtime)-30( )]TJ
T*
[(insulin in type 1 diabetics was evaluated in two 26-week and)-30( )]TJ
T*
[(one 52-week active-controlled clinical trials of more than)-30( )]TJ
T*
[(1100 patients. Safety and ef\036cacy in type 2 diabetics was)-30( )]TJ
T*
[(shown in six studies of more than 2700 patients who were)-30( )]TJ
T*
[(also on oral medications or mealtime insulin. The 70/30)-30( )]TJ
T*
[(combination was evaluated in a study of 362 type 1 diabetics)-30( )]TJ
T*
[(also taking mealtime insulin, and 998 type 2 diabetics in)-30( )]TJ
T*
[(whom the combination was given once or twice a day)92(. In all)-30( )]TJ
T*
[(studies, A1c reductions were in line with reductions achieved)-29.9( )]TJ
T*
(with other previously approved long-acting insulins. )Tj
/CS0 cs 1 scn
/GS1 gs
/C2_1 1 Tf
0 Tc <0084>Tj
ET
endstream
endobj
24 0 obj
<>>>/Subtype/Form>>stream
0 0 0 1 K
3 w 4 M 0 j 0 J
/GS0 gs
q 1 0 0 1 18 754.5 cm
0 0 m
558 0 l
S
Q
endstream
endobj
10 0 obj
<>
endobj
23 0 obj
<>
endobj
25 0 obj
<>stream
application/postscript
AHCmedia(New)_3 tag options_11.8.13
Travis
2014-09-09T14:01:27-04:00
2014-09-09T14:01:27-04:00
2014-09-09T14:01:27-04:00
Adobe Illustrator CC 2014 (Windows)
xmp.iid:bdec626a-762d-6946-8d41-56d8de9e49a7
xmp.did:bdec626a-762d-6946-8d41-56d8de9e49a7
uuid:5D20892493BFDB11914A8590D31508C8
proof:pdf
xmp.iid:13a2ed22-31ef-3e4e-8ae1-9e6a4d59884d
xmp.did:13a2ed22-31ef-3e4e-8ae1-9e6a4d59884d
uuid:5D20892493BFDB11914A8590D31508C8
proof:pdf
converted
from application/pdf to <unknown>
saved
xmp.iid:D27F11740720681191099C3B601C4548
2008-04-17T14:19:15+05:30
Adobe Illustrator CS4
/
converted
from application/pdf to <unknown>
converted
from application/pdf to <unknown>
saved
xmp.iid:F97F1174072068118D4ED246B3ADB1C6
2008-05-15T16:23:06-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:FA7F1174072068118D4ED246B3ADB1C6
2008-05-15T17:10:45-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:EF7F117407206811A46CA4519D24356B
2008-05-15T22:53:33-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:F07F117407206811A46CA4519D24356B
2008-05-15T23:07:07-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:F77F117407206811BDDDFD38D0CF24DD
2008-05-16T10:35:43-07:00
Adobe Illustrator CS4
/
converted
from application/pdf to <unknown>
saved
xmp.iid:F97F117407206811BDDDFD38D0CF24DD
2008-05-16T10:40:59-07:00
Adobe Illustrator CS4
/
converted
from application/vnd.adobe.illustrator to <unknown>
saved
xmp.iid:FA7F117407206811BDDDFD38D0CF24DD
2008-05-16T11:26:55-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:FB7F117407206811BDDDFD38D0CF24DD
2008-05-16T11:29:01-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:FC7F117407206811BDDDFD38D0CF24DD
2008-05-16T11:29:20-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:FD7F117407206811BDDDFD38D0CF24DD
2008-05-16T11:30:54-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:FE7F117407206811BDDDFD38D0CF24DD
2008-05-16T11:31:22-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:B233668C16206811BDDDFD38D0CF24DD
2008-05-16T12:23:46-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:B333668C16206811BDDDFD38D0CF24DD
2008-05-16T13:27:54-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:B433668C16206811BDDDFD38D0CF24DD
2008-05-16T13:46:13-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:F77F11740720681197C1BF14D1759E83
2008-05-16T15:47:57-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:F87F11740720681197C1BF14D1759E83
2008-05-16T15:51:06-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:F97F11740720681197C1BF14D1759E83
2008-05-16T15:52:22-07:00
Adobe Illustrator CS4
/
converted
from application/vnd.adobe.illustrator to application/vnd.adobe.illustrator
saved
xmp.iid:FA7F117407206811B628E3BF27C8C41B
2008-05-22T13:28:01-07:00
Adobe Illustrator CS4
/
converted
from application/vnd.adobe.illustrator to application/vnd.adobe.illustrator
saved
xmp.iid:FF7F117407206811B628E3BF27C8C41B
2008-05-22T16:23:53-07:00
Adobe Illustrator CS4
/
converted
from application/vnd.adobe.illustrator to application/vnd.adobe.illustrator
saved
xmp.iid:07C3BD25102DDD1181B594070CEB88D9
2008-05-28T16:45:26-07:00
Adobe Illustrator CS4
/
converted
from application/vnd.adobe.illustrator to application/vnd.adobe.illustrator
saved
xmp.iid:F87F1174072068119098B097FDA39BEF
2008-06-02T13:25:25-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:F77F117407206811BB1DBF8F242B6F84
2008-06-09T14:58:36-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:F97F117407206811ACAFB8DA80854E76
2008-06-11T14:31:27-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:0180117407206811834383CD3A8D2303
2008-06-11T22:37:35-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:F77F117407206811818C85DF6A1A75C3
2008-06-27T14:40:42-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:2759AC6B4FA8E211B099CEB363CBA397
2013-04-18T13:43:03-04:00
Adobe Illustrator CS4
/
saved
xmp.iid:5E11DEB5A8216811822A8C4A5BB13D00
2014-01-03T17:39:31-05:00
Adobe Illustrator CS6 (Macintosh)
/
converted
from application/postscript to application/vnd.adobe.illustrator
saved
xmp.iid:13a2ed22-31ef-3e4e-8ae1-9e6a4d59884d
2014-01-06T10:41:10-05:00
Adobe Illustrator CC (Windows)
/
converted
from application/postscript to application/vnd.adobe.illustrator
saved
xmp.iid:bdec626a-762d-6946-8d41-56d8de9e49a7
2014-09-09T14:01:27-04:00
Adobe Illustrator CC 2014 (Windows)
/
Print
False
False
1
3.584901
1.584901
Inches
Black
Default Swatch Group
0
White
CMYK
PROCESS
0.000000
0.000000
0.000000
0.000000
Black
CMYK
PROCESS
0.000000
0.000000
0.000000
100.000000
CMYK Red
CMYK
PROCESS
0.000000
100.000000
100.000000
0.000000
CMYK Yellow
CMYK
PROCESS
0.000000
0.000000
100.000000
0.000000
CMYK Green
CMYK
PROCESS
100.000000
0.000000
100.000000
0.000000
CMYK Cyan
CMYK
PROCESS
100.000000
0.000000
0.000000
0.000000
CMYK Blue
CMYK
PROCESS
100.000000
100.000000
0.000000
0.000000
CMYK Magenta
CMYK
PROCESS
0.000000
100.000000
0.000000
0.000000
C=15 M=100 Y=90 K=10
CMYK
PROCESS
15.000000
100.000000
90.000000
10.000000
C=0 M=90 Y=85 K=0
CMYK
PROCESS
0.000000
90.000000
85.000000
0.000000
C=0 M=80 Y=95 K=0
CMYK
PROCESS
0.000000
80.000000
95.000000
0.000000
C=0 M=50 Y=100 K=0
CMYK
PROCESS
0.000000
50.000000
100.000000
0.000000
C=0 M=35 Y=85 K=0
CMYK
PROCESS
0.000000
35.000000
85.000000
0.000000
C=5 M=0 Y=90 K=0
CMYK
PROCESS
5.000000
0.000000
90.000000
0.000000
C=20 M=0 Y=100 K=0
CMYK
PROCESS
20.000000
0.000000
100.000000
0.000000
C=50 M=0 Y=100 K=0
CMYK
PROCESS
50.000000
0.000000
100.000000
0.000000
C=75 M=0 Y=100 K=0
CMYK
PROCESS
75.000000
0.000000
100.000000
0.000000
C=85 M=10 Y=100 K=10
CMYK
PROCESS
85.000000
10.000000
100.000000
10.000000
C=90 M=30 Y=95 K=30
CMYK
PROCESS
90.000000
30.000000
95.000000
30.000000
C=75 M=0 Y=75 K=0
CMYK
PROCESS
75.000000
0.000000
75.000000
0.000000
C=80 M=10 Y=45 K=0
CMYK
PROCESS
80.000000
10.000000
45.000000
0.000000
C=70 M=15 Y=0 K=0
CMYK
PROCESS
70.000000
15.000000
0.000000
0.000000
C=85 M=50 Y=0 K=0
CMYK
PROCESS
85.000000
50.000000
0.000000
0.000000
C=100 M=95 Y=5 K=0
CMYK
PROCESS
100.000000
95.000000
5.000000
0.000000
C=100 M=100 Y=25 K=25
CMYK
PROCESS
100.000000
100.000000
25.000000
25.000000
C=75 M=100 Y=0 K=0
CMYK
PROCESS
75.000000
100.000000
0.000000
0.000000
C=50 M=100 Y=0 K=0
CMYK
PROCESS
50.000000
100.000000
0.000000
0.000000
C=35 M=100 Y=35 K=10
CMYK
PROCESS
35.000000
100.000000
35.000000
10.000000
C=10 M=100 Y=50 K=0
CMYK
PROCESS
10.000000
100.000000
50.000000
0.000000
C=0 M=95 Y=20 K=0
CMYK
PROCESS
0.000000
95.000000
20.000000
0.000000
C=25 M=25 Y=40 K=0
CMYK
PROCESS
25.000000
25.000000
40.000000
0.000000
C=40 M=45 Y=50 K=5
CMYK
PROCESS
40.000000
45.000000
50.000000
5.000000
C=50 M=50 Y=60 K=25
CMYK
PROCESS
50.000000
50.000000
60.000000
25.000000
C=55 M=60 Y=65 K=40
CMYK
PROCESS
55.000000
60.000000
65.000000
40.000000
C=25 M=40 Y=65 K=0
CMYK
PROCESS
25.000000
40.000000
65.000000
0.000000
C=30 M=50 Y=75 K=10
CMYK
PROCESS
30.000000
50.000000
75.000000
10.000000
C=35 M=60 Y=80 K=25
CMYK
PROCESS
35.000000
60.000000
80.000000
25.000000
C=40 M=65 Y=90 K=35
CMYK
PROCESS
40.000000
65.000000
90.000000
35.000000
C=40 M=70 Y=100 K=50
CMYK
PROCESS
40.000000
70.000000
100.000000
50.000000
C=50 M=70 Y=80 K=70
CMYK
PROCESS
50.000000
70.000000
80.000000
70.000000
PANTONE 288 U
SPOT
100.000000
CMYK
100.000000
67.000002
0.000000
23.000000
PANTONE 313 C
SPOT
100.000000
CMYK
100.000000
0.000000
8.000200
13.000500
PANTONE 313 U
SPOT
100.000000
CMYK
100.000000
0.000000
8.000000
13.000000
PANTONE 187 U
SPOT
100.000000
CMYK
0.000000
100.000000
78.999299
19.999699
PANTONE 309 U
SPOT
100.000000
CMYK
100.000000
0.000000
8.999600
72.000098
Grays
1
C=0 M=0 Y=0 K=100
CMYK
PROCESS
0.000000
0.000000
0.000000
100.000000
C=0 M=0 Y=0 K=90
CMYK
PROCESS
0.000000
0.000000
0.000000
89.999400
C=0 M=0 Y=0 K=80
CMYK
PROCESS
0.000000
0.000000
0.000000
79.998800
C=0 M=0 Y=0 K=70
CMYK
PROCESS
0.000000
0.000000
0.000000
69.999700
C=0 M=0 Y=0 K=60
CMYK
PROCESS
0.000000
0.000000
0.000000
59.999100
C=0 M=0 Y=0 K=50
CMYK
PROCESS
0.000000
0.000000
0.000000
50.000000
C=0 M=0 Y=0 K=40
CMYK
PROCESS
0.000000
0.000000
0.000000
39.999400
C=0 M=0 Y=0 K=30
CMYK
PROCESS
0.000000
0.000000
0.000000
29.998800
C=0 M=0 Y=0 K=20
CMYK
PROCESS
0.000000
0.000000
0.000000
19.999700
C=0 M=0 Y=0 K=10
CMYK
PROCESS
0.000000
0.000000
0.000000
9.999100
C=0 M=0 Y=0 K=5
CMYK
PROCESS
0.000000
0.000000
0.000000
4.998800
Brights
1
C=0 M=100 Y=100 K=0
CMYK
PROCESS
0.000000
100.000000
100.000000
0.000000
C=0 M=75 Y=100 K=0
CMYK
PROCESS
0.000000
75.000000
100.000000
0.000000
C=0 M=10 Y=95 K=0
CMYK
PROCESS
0.000000
10.000000
95.000000
0.000000
C=85 M=10 Y=100 K=0
CMYK
PROCESS
85.000000
10.000000
100.000000
0.000000
C=100 M=90 Y=0 K=0
CMYK
PROCESS
100.000000
90.000000
0.000000
0.000000
C=60 M=90 Y=0 K=0
CMYK
PROCESS
60.000000
90.000000
0.003100
0.003100
Adobe PDF library 10.01
endstream
endobj
11 0 obj
<>
endobj
18 0 obj
<>
endobj
19 0 obj
<>
endobj
20 0 obj
<>
endobj
21 0 obj
<>
endobj
22 0 obj
<>
endobj
12 0 obj
<>
endobj
13 0 obj
<>
endobj
14 0 obj
<>
endobj
43 0 obj
<>
endobj
44 0 obj
<>stream
HdNV{q)>J\> i\?m 6eȷ<O/fst]~x{_Nϯ7ww˛oxx2r/?2އp?D??yz{qfzOt:m-_7͆